Street Calls of the Week
Investing.com - Morgan Stanley (NYSE:MS) has assumed coverage of Ascendis Pharma (NASDAQ:ASND) with an Overweight rating and set a price target of $250.00. The stock, currently trading at $173.10 and near its 52-week high of $183, has already delivered a 25% return year-to-date. According to InvestingPro data, analysts’ targets range from $194 to $299, reflecting strong bullish sentiment.
The investment firm’s decision is driven by what it describes as the "promising commercial trajectory" of Yorvipath, Ascendis Pharma’s treatment for hypoparathyroidism.
Morgan Stanley also cited "compelling opportunities" presented by the company’s TransCon pipeline as a factor in its positive outlook on the stock.
The firm noted that market focus remains on Ascendis Pharma’s upcoming second-quarter earnings report, which will provide further insight into the company’s financial performance.
Investors are also awaiting 52-week data from the Phase 2 COACH trial, which Morgan Stanley indicated is expected in the fourth quarter of 2025.
In other recent news, Ascendis Pharma has been the subject of multiple analyst evaluations and updates. UBS maintained its buy rating and $197 price target for Ascendis Pharma, emphasizing the promising launch of Yorvipath and the potential market for hypoparathyroidism treatment. Oppenheimer raised its price target for the company to $224, citing strong demand for Yorvipath among U.S. endocrinologists and indicating that the launch might exceed expectations. TD Cowen reiterated a buy rating with a $194 price target, noting positive results from the Phase 2 COACH trial involving achondroplasia treatment, which could offer additional growth opportunities. RBC Capital also maintained an outperform rating with a $210 price target, highlighting Yorvipath’s steady growth and potential market expansion. Meanwhile, Canaccord Genuity held its rating at $84, expressing cautious optimism about new clinical trial data but noting ongoing concerns about the long-term effects of the combination therapy. These developments reflect a generally positive outlook from analysts, with strong demand and strategic advancements contributing to their assessments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.